INMB News and Press, INmune Bio Inc.

2024-07-05 09:57:38 ET Summary INmune Bio focuses on late-stage therapy for Alzheimer's disease and natural killer cell therapy. XPro is the main focus for Alzheimer's disease, showing promising results with ongoing phase 2 study. Financially, INMB faces cash challenges but co...

The planned interim analysis confirms the accuracy of the sample size calculations and statistical power for EMACC, the primary endpoint. The interim analysis, performed by a third-party, demonstrated no need to change trial design or size. BOCA RATON, Fla., June 27, 2024 (GLOBE N...

2024-06-17 17:58:14 ET Summary An FDA advisory committee voted 11-0 in favor of Eli Lilly and Company's donanemab for the treatment of early Alzheimer's disease. Donanemab has no effect on non-APOE4 carriers, may slow the decline of APOE4 carriers closer to that of non-carriers, a...

2024-06-12 14:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-30 08:23:45 ET More on INmune Bio INmune Bio: An Opportunity In The Freefall (Rating Upgrade) INmune Bio provides update on Alzheimer's candidate XPro INmune Bio rises 2%, on $4.5M direct offering Read the full article on Seeking Alpha For fur...

Boca Raton, Florida, May 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, is set to join the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual r...

2024-05-19 01:10:48 ET Summary Anti-inflammatory drugs are likely to have limited effects on Alzheimer's disease because they are not stopping early oxidation and nitration. Neuroinflammation in Alzheimer's disease is primarily caused by oxidative and nitrosative stress. Inhib...

2024-05-11 20:58:06 ET INmune Bio, Inc. (INMB) Q1 2024 Results Conference Call May 9, 2024 04:30 PM ET Company Participants David Moss - Chief Financial Officer Dr. RJ Tesi - Chief Executive Officer and Co-Founder Dr. Mark Lowdell - Chief Scientific Officer ...

2024-05-09 16:40:03 ET More on INmune Bio INmune Bio: An Opportunity In The Freefall (Rating Upgrade) INmune Bio, Inc. (INMB) Q4 2023 Earnings Call Transcript INmune Bio provides update on Alzheimer's candidate XPro INmune Bio rises 2%, on $4.5M direct offeri...

BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial resu...